Ivonescimab / 伊沃西

Overview

Ivonescimab / 伊沃西 is the episode’s principal case of a Chinese-developed PD-1/VEGF bispecific being compared with K药 and advanced toward multiple regulatory markets.

Current Profile

The source describes one molecule combining immune-checkpoint and tumor-angiogenesis intervention and reports favorable phase-3 results in advanced lung cancer against a PD-1 comparator. It also describes trials in Europe, the United States, Australia, and Japan. The page records that episode account without treating it as an independent trial review or approval record.

Key Characteristics

• Combines two targets in one large molecule rather than using PD-1 inhibition alone.
• Is presented as acting on both immune suppression and tumor blood-vessel formation.
• Serves as a comparative-evidence case against an established global oncology drug.
• Requires multinational trials and regulator-specific evidence for broader market access.

Evidence

• Mechanism and comparator - EP294 一款救命药，要等多少年：中国创新药的崛起之路 describes a dual-target large molecule and compares its reported advanced-lung-cancer phase-3 result with K药.
• Global development - EP294 一款救命药，要等多少年：中国创新药的崛起之路 says the medicine is being studied across several Western and Asian markets to support local regulatory decisions.
• Patient access boundary - EP294 一款救命药，要等多少年：中国创新药的崛起之路 recounts a self-funded chest-cancer case where the relevant indication was not reimbursed, illustrating the distance between drug availability and affordable approved access.

Qualifications

The supplied document is a structured podcast summary and does not provide a trial identifier, protocol, effect size, safety table, regulatory status by country, or primary clinical publication. The single patient story cannot establish general efficacy, safety, or cost-effectiveness.

What Changed

• Established ivonescimab as a focused case linking bispecific design, comparative oncology evidence, multinational development, and indication-specific access.

Relationships

• PD-1/VEGF Bispecific - mechanism category attributed to the drug in the episode.
• Keytruda / K药 - active comparator and incumbent treatment platform.
• Global Clinical-Trial Capability / 全球临床试验能力 - multinational evidence and approval requirement.
• Innovative Drug Payment Sustainability - reimbursement and out-of-pocket access boundary.